In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
BUSINESS
Takeda Less Dependent on Japan, US Revenues Due to Expanding Emerging Market Biz: CCO Morich
Takeda Pharmaceutical has become less dependent on its revenues in Japan and the US, helped by its expanding emerging market operations, Chief Commercial Officer Frank Morich (CEO of Swiss-based Nycomed A/S) stressed on August 28. “The lion’s share of growth…
To read the full story
Related Article
- Takeda Gearing Up for Emerging Market Operations
August 29, 2012
BUSINESS
- Takeda Sheds Working Time by 110,000 Hours via Manufacturing DX
September 9, 2024
- Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
- Vabysmo Filed for Label Expansion into Angioid Streaks in Japan: Chugai
September 9, 2024
- Nippon Shinyaku DMD Med Gets FDA’s Rare Pediatric Disease Tag
September 9, 2024
- Takeda’s Plasma Therapy Ceprotin Now Available in Japan
September 9, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…